Unlock instant, AI-driven research and patent intelligence for your innovation.

Antibody

a technology of antifungal agents and antibodies, applied in the field of antifungal antibodies, can solve the problems of not being able to detect the ia caused, compromising the ability to select the most appropriate antifungal agent,

Inactive Publication Date: 2015-01-15
UNIV OF EXETER
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The LFD demonstrates superior sensitivity and specificity in detecting Aspergillus antigens compared to existing galactomannan and β-glucan tests, enabling early and accurate diagnosis of invasive aspergillosis with minimal training and equipment requirements.

Problems solved by technology

Issues with galactomannan testing.
Issues with galactomannan testing.
Cyclophosphamide induces false-positive results in detection of Aspergillus antigen in urine.
Issues with galactomannan testing.
Clin. Microbiol. Infect. 12:40-52), its lack of specificity means that it is unable to discriminate between Aspergillus species and other opportunistic pathogens, which compromises the ability to select the most appropriate antifungal agent.
In contrast, an ELISA used to detect the Afmp1p cell wall antigen of A. fumigatus in patient's sera provides a high degree of specificity but does not allow the detection of IA caused by other Aspergillus species (Woo, P. C. Y., C-M.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody
  • Antibody
  • Antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

Fungal Culture

[0120]All fungi were cultured on Sabouraud agar (SA) under a 16 h fluorescent light regime.

Development of mAb, Preparation of Immunogen, and Immunization Regime

[0121]Mice were immunized with lyophilized mycelium (LM) of A. fumigatus AF293. Minimal medium (19 mM (NH4)2PO4, 0.5% (wt / vol) yeast extract, 7 mM sodium citrate, 2 mM MgSO4.7H2O, 0.5 mM CaCl2.2H2O and 50 mM glucose, adjusted to pH 5.5 with 1 N HCl) was sterilized by autoclaving at 121° C. for 15 min. Three-wk-old SA Petri dish cultures of the fungus were flooded with 20 ml dH2O and the conidia suspended by gentle agitation using an inoculation loop. Spore suspensions were filtered through Miracloth to remove mycelium and the filtrate containing conidia transferred to 1.5 ml micro-centrifuge tubes. The conidia were washed three times with dH2O by repeated vortexing and centrifugation at 12 000 g for 5 min and finally suspended in dH2O to give a concentration of 106 conidia / ml solution. Flasks containing 150 ml o...

example 2

Summary

[0138]Lectin binding studies show that the antigen(s) bound by MAb JF5 is / are immunogenic N-linked mannoprotein(s) comprising terminal non-reducing mannose residues linked α1-3 and α1-6. Insensitivity of the antigen(s) in ELISA to mild alkaline hydrolysis (β-elimination) shows that the MAb does not bind to glycan structures O-linked through serine and threonine.

Methodology

[0139]Lectin binding studies. Antigen(s) were purified from Aspergillus fumigatus using the method described. Purified antigen solution was subjected to glycoprotein fractionation using a Qproteome Mannose Glycoprotein Kit (Catalog no. 37551; Qiagen Ltd., Crawley, UK) according to the manufacturer's instructions. The ConA, GNA, and LCH lectin spin columns in the kit allow specific enrichment of glycoproteins with mannose-rich glycan moieties. The three lectins each bind different subclasses of these moieties. ConA binds biantennary and triantennary complex type N-glycans; LCH binds biantennary and triantenna...

example 3

Detection of Invasive Pulmonary Aspergillosis by Lateral Flow Technology Compared to Galactomannan and (1-*3)-β-D-Glucan

[0145]Early diagnosis of invasive aspergillosis is critical for the initiation of appropriate antifungal therapy and may improve outcomes in high-risk patients. The use of sensitive biomarkers, including the non-invasive assays for galactomannan and (1→3)-β-D-glucan, also reduces the use of unnecessary antifungal agents. Despite their advantages, the galactomannan and the (1→3)-β-D-glucan assays are confined to laboratories equipped for these tests or require samples be sent to reference laboratories. Lateral-flow technology incorporates immunochromatographic assays into simple devices for point-of-care diagnosis. When coupled to a monoclonal antibody specific to an extracellular glycoprotein of Aspergillus this technology is a sensitive and specific biomarker (Thornton, C. R. 2008. Development of an Immunochromatographic Lateral-Flow Device for Rapid Serodiagnosis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumesaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. application Ser. No. 13 / 144,872, with a 371(c) date of Nov. 7, 2011, which is a National Stage of International Application PCT / GB2010 / 000064, filed Jan. 18, 2010, and U.S. Provisional Appl. No. 61 / 145,282, filed Jan. 16, 2009, which are all hereby incorporated by reference herein in their entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted via EFS-Web on Nov. 7, 2011 for U.S. application Ser. No. 13 / 144,872, and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 29, 2014, is named 0087EU01.txt and is 51,335 bytes in size.FIELD OF THE INVENTION[0003]This invention relates to a method of diagnosing a fungal infection, and to antibodies and related molecules for use in such a method.BACKGROUND[0004]The dramatic increase in opportunistic infections of humans caused by Aspergillus species over the last decade ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/14G01N33/569
CPCC07K2317/565C07K16/14G01N2333/38G01N33/56961A61P31/10C07K2317/56G01N2469/20
Inventor THORNTON, CHRISTOPHER
Owner UNIV OF EXETER